Pfizer Inc.’s new respiratory syncytial virus (RSV) vaccine Abrysvo is off to a strong start, generating $375m in the third quarter after launching just in time for the fall season for older adults. Abrysvo was a positive development for Pfizer in a challenging quarter marked by lower sales of its two COVID-19 products – the vaccine Comirnaty and the antiviral Paxlovid.
Abrysvo Launch A Bright Spot For Pfizer In A Third Quarter Reset
The RSV vaccine performed well in the third quarter but is in a competitive fight with GSK’s Arexvy. Pfizer also announced Phase III results for its mRNA-based flu vaccine.
More from Earnings
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.